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The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Purchasing 
Authorities Chief Executives (PACE) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development, The Scottish Health Purchasing Information Centre 
(SHPIC) and The University of Birmingham Department of Public Health and Epidemiology. 
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EXECUTIVE SUMMARY 
 
Lymphoma and High Dose Chemotherapy 
 Lymphomas are malignancies of the lymphoreticular system, which provides part of the 
body’s natural defence against infection. Malignant lymphomas are categorised into two 
distinct disease types based on their underlying pathology, Non-Hodgkin’s Lymphoma 
(NHL) and Hodgkin’s Disease (HD). 
 Current standard treatments for lymphoma are based on a combination of radiotherapy 
and chemotherapy, and depend on the type and stage of the disease.  However, for 
more advanced stages of disease, the use of high dose chemotherapy (HDC) is 
becoming an increasingly common treatment option. Due to the high doses of drugs 
used, HDC causes irreversible bone marrow toxicity and requires patients to have follow-
up blood support with either bone marrow transplantation (BMT) or, as has been the case 
more recently, with peripheral blood stem cell transplantation. In the case of lymphoma, 
these transplants are in the majority of cases autologous, using stem cells taken from the 
patients themselves via harvesting techniques. 
 The European Blood and Marrow Transplant Registry (EBMT) is a collaborative group 
established in the 1980s which has drawn up draft accreditation guidelines for High Dose 
Chemotherapy Centres and these are likely to become accepted as minimum standards. 
 The estimated cost of providing stem cell harvesting and HDC is £15,600.  The estimated 
cost of standard salvage chemotherapy is £1,500 including an approximate 50% chance 
of further admission with neutropenic sepsis. 
 
Non-Hodgkin’s Lymphoma 
 There are approximately 4,200 cases of NHL reported annually in England and Wales, 
approximately 8.0 per 100,000 per annum, with an underlying 3% increase in incidence. 
In 1994 there were 610 (288 female, 322 male) new registrations within the Trent Region.  
 NHLs are a heterogeneous group of malignancies which tend to present and respond to 
treatment in very different ways. From a practical point of view, many clinicians divide 
NHL into low grade/indolent lymphomas and intermediate/high grade lymphomas. 
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 Low grade lymphoma accounts for around 30% - 35% of NHL, and is an indolent, 
insidious disease state which often has few symptoms and is often slow growing. Low 
grade NHL is characterised by a relapsing and remitting course with a median survival of 
between seven and nine years. High grade NHL accounts for around 65% - 70% of NHL 
and is an aggressive malignancy, treated mainly with combination chemotherapy. 
Approximately 80% of patients will achieve a complete remission with combination 
chemotherapy, but many relapse and only 40% of patients will be long-term survivors. 
There were 331 deaths from NHL within the Trent Region in 1994.  Five year survival    
rates for NHL are 44% male and 42% female within Trent. 
 The EBMT recommends the use of HDC in poor prognosis high grade NHL and first 
relapse high grade NHL.  The EBMT suggests continued clinical trial in low grade NHL. 
The overall survival benefit of HDC in first relapse NHL is 13 months based on the Parma 
randomised controlled trial. This increases to 23 months when projecting benefits five 
years beyond the trial. 
The cost per life year gained (LYG) for HDC in NHL based on trial data only is £12,818. The 
cost per LYG for HDC in NHL including five year projected benefits is £6,130. 
 
Hodgkin’s Disease 
 There are approximately 1,100 new cases of HD reported each year in England and 
Wales, approximately 2.0 per 100,000 per annum.  In 1994 there were 89 registrations of 
Hodgkin’s disease within the Trent Region. There were 28 deaths from HD within the 
Trent Region in 1994.  Five year survival rates for HD are 75% male and 61% female 
within Trent. 
 Using established chemotherapy and radiotherapy regimens, over 80% of all patients can 
be cured of HD. Failure to achieve a complete response to treatment or relapse soon 
after chemotherapy is a poor prognostic factor. 
 The EBMT recommends the use of HDC in first and subsequent relapsed HD, mantle cell 
lymphoma and lymphoblastic lymphoma. 
 The overall survival benefit of HDC in relapsed and poor prognosis HD is 10 months 
based on the BNLI-Linch RCT. This increases to 19 months when projecting benefits five 
years beyond the trial. 
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The cost per LYG for HDC in HD based on trial data only is £17,625.  The cost per LYG for 
HDC in HD including five year projected benefits is £6,130. 
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1. INTRODUCTION  
 
1.1 Lymphoma: Background to Disease 
 
Lymphomas are malignancies of the lymphoreticular system, which provides part of the 
body’s natural defence against infection. Lymphoid tissue is found in most organs of the 
body and major groups of lymph nodes are found in the neck, ascillar, mediastinum, 
abdomen and groin. The tonsils, spleen and bone marrow are also considered as part of the 
lymphatic system.  
 
Malignant lymphomas are categorised into two distinct disease types based on their 
underlying pathology, Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD). Non-
Hodgkin's lymphoma is a much more heterogeneous group of conditions with a wide variety 
of histological types, clinical behaviour and treatment protocols. HD has well standardised 
histological classification, staging criteria and treatment protocols and accounts for 
approximately 20-30% of all lymphomas.  
 
Current standard treatments for lymphoma are based on a combination of radiotherapy and 
chemotherapy, and depend on the type and stage of the disease.  However, for more 
advanced stages of disease the use of high dose chemotherapy (HDC) is becoming an 
increasingly common treatment option, particularly with patients who have either relapsed 
after complete remission or have only achieved a partial response to standard treatment. 
Due to the high doses of drugs used, HDC causes irreversible bone marrow toxicity and 
requires patients to have follow-up blood support with either bone marrow transplantation 
(BMT) or, as has been the case more recently, with peripheral blood stem cell 
transplantation (PBSCT). In the case of lymphoma, these blood stem cell product 
transplants are in the majority of cases autologous, using blood stem cells taken from the 
patients themselves via harvesting techniques.  
 
This increase in the use of HDC has not been based necessarily on a firm body of 
established randomised controlled trial (RCT) evidence. Much of the use of HDC has 
followed the positive results of smaller trials and studies. 
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The aim of this Guidance Note is to summarise the clinical evidence for HDC in the 
treatment of lymphomas, considering specific prognosis groups: complete remission; high 
risk; partial remission; first relapse; subsequent relapse. The Guidance Note also makes 
reference to an ongoing Health Technology Assessment (HTA) systematic review which is 
currently considering HDC treatment across a series of malignancies, including lymphoma. 
 
Finally, the Guidance Note presents the potential cost-effectiveness of HDC when 
considered in patient groups where clinical effectiveness is confirmed by RCTs. 
 
1.2 Non-Hodgkin’s Lymphoma 
 
1.2.1 Aetiology and Incidence 
Non-Hodgkin's Lymphoma (NHL) is a heterogeneous group of conditions of which the 
incidence is rising by approximately 3% per year. There is an increased incidence 
associated with immunosuppression, autoimmune diseases, certain congenital disorders 
and AIDS.  There appears to be a link to certain chemicals including hair dyes and 
pesticides.  However, the cause for the rise in incidence is not immediately apparent and it 
does not appear to be solely accounted for by improvements in diagnostic techniques, 
registration of cases or increased prevalence of immunosuppressed patients. One third of 
cases are extra-nodal and may involve the skin, the gastrointestinal tract or any other 
organ.  
There are approximately 4,200 cases of NHL reported annually in England and Wales, with 
610 (288 female, 322 male) new registrations in the Trent Region in 1994.  Crude incidence 
rates for Trent in 1994 are 11.9 per 100,000 per annum for females and 13.6 per 100,000 
population per annum for males. 
 
1.2.2 Histology 
The histological classification of NHL is controversial. The Revised European-American 
classification of Lymphoma (REAL), based on cell lineage, morphology and distinct clinical 
entities, has now superseded the Working Formulation, which was based on cell lineage, 
cell type and grade.  From a practical point of view, many clinicians divide NHL into low 
grade/indolent lymphomas and intermediate/high grade lymphoma.   
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Figure 1   Trent Non-Hodgkin’s Lymphoma Incidence Rate 1985-1994 
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Source: Trent Cancer Registry 
 
Non-Hodgkin's lymphoma is more common in older age groups and shows a male 
preponderance. 
 
Figure 2  Trent Age/Sex Non-Hodgkin’s Lymphoma Notifications 1985-1994 
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1.2.3 Clinical Features 
These are similar to those for HD, but patients often have widely disseminated disease. 
Bone marrow and extralymphatic organ involvement occurs more frequently than in HD and 
there may be an associated haemolytic anaemia or paraproteinaemia. 
1.2.4 Staging 
Staging is as for HD. The Ann Arbor classification is usually applied, although it is not 
always appropriate. 
1.2.5 Treatment and Prognosis 
Non-Hodgkin’s Lymphomas are a heterogeneous group of malignancies which tend to 
present and respond to treatment in very different ways. They can be divided broadly into: 
 
i) Low Grade NHL  
Accounting for around 30% - 35% of NHL, low grade NHL is an indolent, insidious 
disease state which often has few symptoms at presentation and is often slow growing. 
Pathogenesis is characterised by a relapsing and remitting course with a median 
survival of between seven and nine years. Most patients present with disseminated 
disease.  Treatment does not improve survival but is used for symptom control, and is 
usually with alkylating agents such as chlorambucil or with combination chemotherapy.  
Radiotherapy is very effective for control of local symptoms.  A significant proportion of 
these low grade lymphomas subsequently transform into high grade lymphomas with a 
very poor prognosis. 
 
ii) High Grade NHL  
High grade NHL accounts for around 65% - 70% of NHL and is an aggressive 
malignancy, treated mainly with combination chemotherapy. Approximately 80% of 
patients will achieve a complete remission with combination chemotherapy but many 
relapse and only 40% of patients will be long-term survivors. Various initial 
chemotherapy regimens exist, but the gold standard remains CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisolone).  A number of prognostic 
factors have been identified. These include age, stage, performance status, serum 
lactoase dehydrogenase (LDH) and involvement of extranodal sites.  A prognostic 
score, the International Index, has been constructed and can predict those patients with 
a low probability of cure with conventional chemotherapy. 
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1.3 Hodgkin’s Disease 
 
1.3.1 Aetiology and Incidence 
The incidence of HD is approximately 2.0 per 100,000 per year and is gradually falling. 
There are approximately 1,100 new cases reported each year in England and Wales.  In 
1994 there were 89 registrations of HD (44 female, 45 male)  within the Trent Region, 
slightly lower than the expected national average. This translates into a crude incidence rate 
of 1.82 per 100,000 population per annum for females and 1.91 per 100,000 population per 
annum  
for males in 1994.
1,2 
Figure 3  Trent Hodgkin's Disease Registration Rates 1994 
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Source: Trent Cancer Registry 
There is a bimodal peak age incidence with one peak occurring at 15-34 years of age and the other 
after 50 years.  There is a slight male preponderance in notification rates, see Figure 2. 
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Figure 4   Trent Age/Sex Hodgkin's Disease Notifications 1985-1994 
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Source: Trent Cancer Registry 
 
The aetiology of HD is unknown, but there is mounting evidence to implicate Epstein-Barr 
Virus in at least one of the sub-types, with presence in 40% to 50% of HD cases.  
1.3.2 Clinical features   
Two thirds of cases present with cervical lymphadenopathy, although any lymph node group 
or extra nodal site may be involved.  Patients may also complain of B symptoms i.e. high 
swinging temperatures, drenching sweats and weight loss of >10% of their body weight. 
Other symptoms may include pruritus, alcohol induced pain and a variety of other 
constitutional symptoms. 
1.3.3 Diagnosis  
A number of non-specific findings are commonly found including anaemia or raised 
Erythrocyte Sedimentation Rate (ESR). Diagnosis is established by demonstrating 
histological evidence of HD in a biopsy, usually of a lymph node. The cell type felt to be 
characteristic is the bi-nucleate Reed-Sternberg cell. This type of cell is specific to HD. 
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1.3.4 Histological classification  
There are four main histological sub-types of HD in the Rye classification 
a)   Nodular sclerosing  - accounts for 70% of cases 
b)   Lymphocyte predominant - accounts for 15% of cases 
c)   Mixed cellularity   - accounts for 10% of cases 
d)   Lymphocyte depleted  - accounts for 5% of cases 
 
1.3.5 Staging 
The stage of HD is currently classified using the Ann Arbor staging classification, developed 
in 1971, and later revised in 1989. 
 Stage 1 - involves one lymph node group; 
 Stage 2 - involves two or more lymph node groups; 
 Stage 3 - involves lymph node groups on both sides of the diaphragm; 
 Stage 4 - involves the extra nodal tissue, including bone marrow, liver, bone, lung, etc. 
 
The staging of disease also takes into account the presence of a range of general 
symptoms: 
 unexplained loss of body weight (>10% of pre-diagnosis weight); 
 drenching night sweats; 
 unexplained fever (>38 degrees C). 
 
Patients are further sub-categorised within stage as:  
 A - no general symptoms; 
 B  - presence of general symptoms. 
A higher stage has a worse prognosis, and the presence of B symptoms indicates a worse 
prognosis independent of stage.  A number of other prognostic factors have also been 
identified including lymphocyte count, lactoase dehydrogenase (LDH) and ESR.  Prognostic 
scores have been constructed to identify patients with a poor prognosis.  Clinical staging is 
carried out with a CT scan of the thorax and abdomen, chest X-ray and, where indicated, 
bone marrow trephine and aspiration.   
1.3.6 Treatment 
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There are two effective treatments for HD, radiotherapy and combination chemotherapy.  
Radiotherapy is curative in HD if all the disease is treated with an adequate dose.  Stages 
IA, IB and IIA disease are usually treated with radiotherapy although there is increasing 
evidence that a combination of low dose chemotherapy and involved field radiotherapy may 
be equally effective with reduced toxicity.  Chemotherapy using four or more drugs, 
including an anthracycline, is used for stage IIB to stage IV disease.  The gold standard 
regimen in the UK is currently an alternating regimen comprising eight drugs.  This is 
currently being compared to the US gold standard of four drugs in a large national 
randomised controlled trial. 
 
Using established chemotherapy and radiotherapy regimens, over 80% of all patients can 
be cured of HD.  The chance of cure lessens with increasing stage, being >95% for stage I 
and approximately 60% for stage IV. Failure to achieve a complete response to treatment, 
or relapse soon after chemotherapy are both poor prognostic factors. 
 
1.4 Prognosis and Mortality  
 
The prognosis of both HD and NHL varies considerably according to the type and stage of 
the disease.  
 
Prognosis is excellent for early stages of HD and is improving for all stages due to 
improvements in treatment. For more advanced stages, around 50% have long-term (over 
10 year) survival. 
 
Table 1 Overall Relative Survival Estimates - Hodgkin’s Disease 
Hodgkin’s Disease 1 year 3 year 5 year 
Male 85% 79% 75% 
Female 80% 66% 61% 
Source : Trent Cancer Registry 
 
Prognosis for NHL is poorer, especially for stages III and IV, and is adversely affected by 
factors such as age. Some types of low grade NHL are also associated with a poor 
prognosis. 
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Table 2 Overall Relative Survival Estimates - Non-Hodgkin’s Lymphoma 
Non-Hodgkin’s Lymphoma 1 year 3 year 5 year 
Male 59% 46% 44% 
Female 55% 45% 42% 
 
There were 28 deaths from HD and 331 deaths from NHL within the Trent Region in 1994. 
 
1.5 Scale of Problem in a ‘Typical’ District  
 
In a 'typical' district of 500,000 people there would be approximately: 
 
 15 newly reported cases of low grade NHL per annum; 
 35 newly reported cases of high grade NHL per annum; 
 10 newly reported cases cases of HD per annum. 
 
Within Trent HDC with stem cell transplantations are already being routinely used for 
patients with both relapsed HD and relapsed high/intermediate grade NHL.  
 
1.6 European Blood and Marrow Transplant Registry 
The European Blood and Marrow Transplant Registry (EBMT) is a collaborative group 
established in the 1980s.  The aims of the EBMT include: 
 Collection of clinical data on patients undergoing HDC; 
 Sponsorship of large clinical trials in HDC; 
 Development of minimum standards and accreditation guidelines for HDC. 
 
The EBMT is comprised of a number of sub-groups with responsibility for the major tumour 
types commonly treated with HDC, e.g. lymphoma, solid tumours, leukaemias, paediatric 
malignancies etc. 
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In the UK, a subsidiary group, The British Society for Blood and Marrow Transplantation 
(BSBMT) has recently been established.  Membership of the EBMT and BSBMT is 
voluntary; there is no obligation on clinicians to register their data with these organisations.  
However, there is a general consensus that, given the morbidity, mortality and cost 
implications of these treatments, patients not in clinical trials should have their data 
recorded. Data from EBMT for 1996 are now available and clearly show the commonest 
indications for HDC. 
 
Table 3 High Dose Chemotherapy Notifications from EBMT Data 
Disease Area Notifications 
Non-Hodgkin’s Lymphoma 2,645 
Breast cancer 2,156 
Acute myeloid leukemia (AML) 1,878 
Multiple myeloma 1,856 
Chronic myeloid leukemia (CML) 1,382 
Acute lymphoblastic leukemia (ALL) 1,275 
Hodgkin’s Disease   739 
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2. THE USE OF HIGH DOSE CHEMOTHERAPY AND STEM CELL 
TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA AND HODGKIN'S 
DISEASE: SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1 Introduction to Treatment for Non-Hodgkin’s Lymphoma  
 
High dose chemotherapy, with the use of stored autologous bone marrow to rescue the 
patient from otherwise potentially lethal haematological toxicity, began to be used in 
significant numbers of patients with NHL in the late 1970s.
3
   
 
The evaluation of HDC progressed through a number of stages.  Initial studies were small 
phase II single institution studies.  The procedure was initially performed in patients with 
extremely poor prognosis for whom it offered the only prospect of a cure.  In the early 1980s 
the results of larger studies from collaborating, pioneering centres in co-operative groups 
began to suggest that remissions, if not cures, were possible.
4
 
 
Peripheral blood is an alternative source to bone marrow of haematopoietic progenitors  for 
transplantation after ablative therapy.  Peripheral blood progenitor cells (PBPC) have the 
following advantages over bone marrow: 
 
 Earlier engraftment leading to reduced procedure-related morbidity and mortality; 
 
 No requirement for a general anaesthetic for the procedure to harvest the cells; 
 
 Reduced risk of malignant contamination. 
 
Over the last few years, there has been a rapid shift to the use of PBPC compared with 
bone marrow to support ablative chemotherapy.
5,6,7,8,9,10
 
 
2.2 Intermediate and High Grade Non-Hodgkin’s Lymphoma 
 
2.2.1 HDC as Therapy in First Relapse Non-Hodgkin’s Lymphoma  
 
 15 
Approximately 70-80% of patients with high grade NHL achieve a complete response with 
first line chemotherapy, but a significant proportion relapse.  
Parma Trial (Phillip) 
In an initial pilot study, the Parma Group found that salvage chemotherapy followed by 
radiotherapy to the involved field, HDC and autologous bone marrow transplantation (ABMT) 
resulted in prolonged remissions in 40% of patients who had treatment sensitive lymphoma 
in relapse.
11
  A further Parma randomised phase III controlled trial of 215 patients with 
relapsed NHL showed an initial response rate of 84% after HDC and 44% after standard 
salvage treatment.  At five years the event-free survival was 46% in the high dose arm and 
12% in the standard arm (p=0.001) and the overall survival rate was 53% in the high dose 
arm and 32% in the standard arm.
12,13
 
 
A subsequent analysis of time to relapse in patients who received salvage chemotherapy  
showed that patients who relapsed within 12 months of the initial diagnosis had a high 
probability of relapse with resistant disease and suggested that this group of early relapse 
patients should be selected for further phase II studies, perhaps including double high dose 
procedure.  However, even in this group, HDC was superior to conventional treatment.
14
 
 
Summary: Based on these data, HDC with haematological rescue became standard 
treatment for patients with relapsed high grade NHL in sensitive relapse.
12,13  
The Parma 
study is the only phase III trial in first relapse NHL. 
 
2.2.2 HDC as Therapy in First Remission Intermediate and High Grade NHL 
 
Patients with a high risk of relapse or failure to achieve complete remission after initial 
chemotherapy can be identified using the International Prognostic Index
15
. The long-term 
survival in this group of patients is in the order of 30%. 
 
GELA Trial LNH-87 (Haioun) 
The GELA group (Group D’Étude des Lymphomas de l’Adulte) carried out a randomised 
study comparing HDC with intermediate dose consolidation in patients in first complete 
remission with intermediate and high grade NHL. After induction 464 patients were 
assessable.  With a median follow-up duration of 28 months, the three year disease-free 
survival rate was 52% in the standard arm and 59% in the high dose arm.
16
  However, sub-
group analysis showed that patients with at least two adverse prognostic factors who 
received HDC did better than those in the standard arm.  Five year disease-free survival 
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was significantly higher in the ABMT arm (57 vs 36%, p=0.01) in the high-intermediate and 
high risk groups (2-3 factors, 236 patients); the 5-year survival rate also differed (65% vs 
52%, p=0.06)
16,17
  It was noticed in the study that only 65% of patients achieved a complete 
remission with their initial chemotherapy.   
 
A non randomised comparison of conventional chemotherapy versus dose intensified plus 
consolidation HDC with peripheral blood progenitor cell rescue showed a significant 
reduction in event-free (61% vs 35%) and overall survival (64% vs 35%) at two years follow-
up.  There were 34 patients in the standard arm and 33 patients in the high dose arm.
18
 
 
2.2.3 HDC as an initial therapy in High Grade Non-Hodgkin’s Lymphoma 
In view of the success of HDC in salvaging patients with relapsed high grade NHL and the 
ability to identify patients at high risk of relapse, investigators have also examined the effect 
of incorporating HDC early in the initial treatment regimen. 
 
GELA Group Trial - LNH 93-3 (Gisselbrecht)
19
 
The GELA group reported a randomised comparison of standard chemotherapy with CVB 
versus a short high intensive therapy with HDC on day 60, the LNH 93-3 protocol.
12
 302 
patients with intermediate or high grade lymphoma with at least two adverse prognostic 
factors were included.  The rate of induction failure was similar in both arms.  With a median 
follow-up of 16 months, event-free survival was 57% in the standard arm and 48% in the 
high dose arm (p=0.02) and overall survival 73% in the standard arm and 61% in the high 
dose arm (p=0.01).  A short induction treatment with HDC did not increase complete 
response rates when compared with standard treatment in this group. 
 
INT Group Trial (Gianni)
20 
A further study carried out by the INT Group looked at intensive initial induction 
chemotherapy followed by early HDC treatment compared with standard alternating 
chemotherapy in adults with poor prognosis high grade NHL. 98 eligible patients were 
randomised to receive either standard or high dose sequential therapy.  If the assigned 
treatment failed, the study design allowed patients to cross over to the other arm.  After a 
follow-up of 55 months, the patients given high dose sequential therapy had a significantly 
higher rate of complete response when compared with the standard arm (96% versus 70%, 
p=0.001,) freedom from disease progression (84% versus 49%, p=0.001,) freedom from 
relapse (80% versus 70%, p=0.005,) and event-free survival (76% versus 49%, p=0.004.)  
Overall survival of seven years was better in the high dose arm, 81% versus 55%, but this 
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did not reach significance at conventional level (p=0.09.)  Of note with this study, only 5% of 
those patients who failed standard chemotherapy could be salvaged by HDC, significantly 
lower than in other published studies.
20
 
 
Summary: The place of HDC as initial treatment in high risk NHL remains unclear. A number 
of large studies are currently being undertaken by both the European Organisation for the 
Research and Treatment of Cancer (EORTC) and by the British National Lymphoma 
Investigations (BNLI). In addition, two randomised studies from a Dutch group and from the 
National Cancer Institute (NCI) completed recruitment in 1993 and results are awaited. 
 
2.2.4 High Dose Chemotherapy in Patients with Incomplete First Response to First Line
 Chemotherapy. 
 
The role of HDC in patients with NHL who have had a slow or incomplete response to initial 
chemotherapy has also been examined by a number of groups. 
 
Martelli Trial
21
 
An Italian co-operative group randomised 286 patients between two different alternating 
regimens F-MACHOP-B versus MACOP-B.  Seventy seven (27%) patients had achieved 
only a partial response after completing two thirds of the first line chemotherapy and 49 
(64%) of these were randomised to either standard salvage therapy with DHAP (27) or high 
dose chemotherapy with Busulphan, Etoposie, Cytarabie, Melphalan (BEAC) + Autologous 
Bone Marrow Transplantation (ABMT).  The overall response rate was better in the high 
dose arm (96% vs 59%, p<0.001.)  Projected progression-free survival at 55 months was 
59% and 52% respectively and overall survival 73% and 73%.  Neither was significant at 
conventional levels.  The numbers studied were felt to be too small for a conclusion to be 
drawn. 
 
Dutch/Belgian Trial
22
  
A Dutch collaborative group randomised 69 patients with only a partial response after three 
cycles of CHOP to either ABMT or a further five cycles of CHOP. At four years, the overall 
survival was 85% in the CHOP group and 56% in the ABMT arm. The disease-free survival 
at four years was 72% and 60% respectively and the event-free survival 53% and 41% 
respectively.  The authors concluded that there did not appear to be any advantage to the 
early use of HDC in patients with high grade NHL with a slow response to first line CHOP 
chemotherapy. 
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A non-randomised study from Canada
23
 reported the results of 36 patients with NHL who 
had failed to achieve a complete remission with standard induction chemotherapy and who 
received HDC and ABMT rescue. The predicted three years overall survival (OS) was 51% 
and event-free survival (EFS) 39% with 28 months follow-up. In a similar group of patients 
with HD the EFS and OS at 35 months were 51% and 34% respectively. 
 
Summary: To date, there is no proven survival advantage to early HDC in patients with a 
slow or incomplete response to CHOP chemotherapy. 
 
2.3 Low Grade Non-Hodgkin’s Lymphoma 
2.3.1 Follicular lymphoma 
Follicular lymphoma comprises 80% of low grade lymphoma. During the past 30 years, little 
significant progress has been made in the treatment of patients with advanced follicular 
NHL.  Although the median survival time is 8-9 years, virtually all patients finally die of their 
disease after experiencing multiple remissions and relapses.  Remissions can be induced 
either by single drug treatment, combination chemotherapy or chemotherapy followed by 
radiotherapy.  However, none of these treatments has been shown to be associated with a 
survival advantage.  A number of recent phase II clinical studies employing HDC and 
autologous stem cell rescue in patients with relapsed low grade malignant NHL have shown 
disease-free survival ranging between 60 and 85% at a median follow-up of 3-7 years.  
While these results are very encouraging, formal evaluation in randomised controlled trials is 
needed.
24
 
2.3.2 Mantle Cell 
Mantle cell lymphoma is an uncommon form of lymphoma previously classified as low 
grade,which is now being increasingly identified. It has a characteristic cytogenetic 
abnormality and is associated with poor prognosis; median survival is less than five years 
and less than 10% of patients are alive at 10 years. Patients usually present with 
widespread disease. Unlike most other types of lymphoma, mantle cell lymphoma is 
relatively chemotherapy resistant with a complete response rate of <30%. There may be a 
trend towards increased survival with anthracycline-based chemotherapy. In view of this 
resistance to conventional therapy, investigators have evaluated the role of HDC in first 
remission. There are no randomised controlled trials to date, but data from phase II studies 
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are mixed. The EBMT recommends HDC in first complete remission in mantle cell 
lymphoma. 
 
The BNLI and EORTC are currently collaborating in a trial assessing the role of HDC as first 
line therapy in low grade NHL. 
 
2.4 Lymphoblastic Lymphoma 
 
Lymphoblastic Lymphoma (LBL) is a distinct sub-type of NHL. Characteristic features 
include male predominance, an increased incidence in adolescence and young adults and 
frequent mediastinal involvement at presentation.  Bone marrow involvement is common 
and progression to leukaemic phase is a recognised terminal event.  The clinical and 
pathological distinction between LBL and acute lymphoblastic leukaemia (ALL) is unclear.  
The two diseases have close morphologic and phenotypic similarities and overlap clinically.  
LBL in adults is a rare disease, accounting for approximately 4% of all adult patients with 
NHL.  Therefore, it has been the subject of a relatively small number of studies.  Early 
studies of childhood and adult LBL patients, treated with first and second generation 
chemotherapy regimens designed for intermediate grade NHL, reported poor results with 
long-term disease-free survival of only 15-30%.  Substantial improvements in long-term 
survival were reported in the 1970s for children treated with regimens similar to those used 
for ALL and intensive chemotherapy and radiotherapy regimens for this type were 
subsequently adopted for adult patients, with an improvement in long-term, disease-free and 
overall survival to 40-60% in most series. 
 
High dose chemotherapy has recently been used with encouraging results as consolidation 
of first remission in patients with LBL. 
 
A review of 214 patients with LBL, reported to the EBMT between January 1981 and 
December 1992, included 105 patients undergoing HDC in first complete remission.  The 
actuarial overall survival rate at six years for the entire group was 42%.  Disease status at 
ABMT was the major determinant of outcome; six year actuarial overall survival was 63% for 
patients transplanted in the first complete remission compared with 15% of those with 
resistant disease at the time of transplantation. A second complete remission resulted in a 
31% overall survival of six years. 
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The initial results of a randomised study carried out by the UK Lymphoma Group, comparing 
standard induction chemotherapy followed by either ‘leukaemia style’ maintenance therapy 
for 18 months or HDC have recently been reported. One hundred and eleven patients have 
entered the study. Patients with human leukocyte antigen (HLA) identical sibling donors 
were registered in the trial but treated with allogeneic BMT without randomisation in some 
centres.  Data are currently available on the first 95 patients who entered the trial. Forty nine 
patients were randomised to maintenance chemotherapy or HDC. The actual overall survival 
at 18 months for all registered patients is 52%. Data for the individual treatment arms have 
yet to be published.  
 
In the recently reported review from EBMT, allogeneic BMT was associated with a lower 
relapse rate than ABMT (24% versus 48%). The progression-free survival, however, was not 
significantly different because of the higher procedure related mortality.
25
 
 
A number of small phase II studies have been carried out.
26,27,28
 
 
2.5 Hodgkin’s Disease 
With the use of MOPP, MOPP alternatives such as MVPP and ABVD or hybrid regimens 
such as ChlVPP/PABlOE, the majority of patients with advanced HD can now be cured of 
their disease.  However, a number of patients fail conventional treatment. Patients in whom 
chemotherapy fails can be divided into several important sub-groups based on the response 
to the initial chemotherapeutic regimens.   
 
These include:  
 patients with primary-refractory disease; 
 patients who relapse within 12 months of completing chemotherapy;  
 patients with multiple relapses. 
 
Reported series have tended to include patients from all these patient groups. 
2.5.1 HDC in Relapsed or Primary Refractory Hodgkin's Disease 
A review of 107 patients with Hodgkin’s Disease treated with combination chemotherapy at 
the National Cancer Institute showed that in those patients who did not achieve a complete 
 21 
remission, relapsed within one year of completing treatment, or had more than one relapse, 
the chances of long-term survival were less than 20%.
29
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i) BNLI Trial (Linch) 
A single RCT has been reported by the BNLI.  Twenty patients with relapsed disease 
received sub-ablative chemotherapy with mini-BEAM and a further 20 received BEAM plus 
ABMT.  The study closed early because of poor recruitment.  There was a significant 
advantage for both event-free survival and progression-free survival in the HDC arm.
30
 
 
The remaining evidence of effectiveness comes from a combination of smaller trials and 
observational studies. 
 
Observational Studies 
In one of the most quoted studies, University College Hospital, London reported a series of 
155 poor risk HD patients who received HDC. All had either not attained a remission on 
MOPP type therapy and had poor prognostic features at presentation, not attained a 
complete remission or relapsed within one year after an initial alternating regimen or had 
failed two or more lines of treatment. The actuarial overall and progressive-free survival at 
five years were 55% and 50% respectively.
31
 
 
Gianni et al.
32
 reported on 25 patients with either refractory (seven patients), partial 
response (nine patients) or early relapse (nine patients) following induction chemotherapy 
with MOPP/ABVD. Event-free survival at six years was 78% for those with short initial 
complete responses and 31% for patients who had primary-refractory disease. 
 
Fifty one patients with either primary-refractory or relapsed HD were treated by a German 
group
33
 with salvage chemotherapy followed by HDC. Patients had received a median of 
three different courses of chemotherapy and 84% had received radiotherapy either as 
involved field, mantle, inverted Y or total nodal irradiation. Eight patients had primary 
refractory disease. With a median follow up of 12 months, overall survival was 61% and 
progression-free survival 44%. 
 
Armitage et al.
 34
 reported the use of CVB and ABMT in 70 patients treated between 1984-
88. Overall survival at four years was 47% and disease-free survival was significantly better 
for those patients treated in first relapse as compared to those treated in subsequent 
relapse. 
 
A French study examined 100 patients with HD who had either failed to respond to front line 
chemotherapy (n=41) or relapsed, (n=59) and were treated with salvage chemotherapy 
 23 
followed by HDC.
35
 59% of patients had achieved a complete response with a re-induction 
chemotherapy and 72 patients went on to receive HDC. The estimated two year survival for 
the 100 patients was 59%, or 61% of those who received HDC. However, 47 of the 72 
patients who received HDC had either not responded to, or only achieved a partial remission 
with, re-induction chemotherapy. 
 
A further study looking at the role of HDC with CBV and ABMT in relapsed HD after two 
lines of chemotherapy reported an event-free and overall survival rate at five years of 53% 
and 47% respectively.
36
 
 
A retrospective analysis of 86 patients with refractory HD from 14 centres in France treated 
with ablative chemotherapy showed that with a median follow-up of 29 months, the overall 
survival was 35%. Comparative data from the EORTC, Group D'Étude des Lymphoma de 
l'Adulte (GELA) and IDHG databases showed that the reference population had a five year 
survival of 20%.
37
 
 
A review of the EBMT data for 290 patients treated with primary-refractory HD between 
1979-1995 showed an actuarial five year progression-free survival and overall survival to be 
30% and 31% respectively.
38
 
 
The use of CBV +/- cisplatin has been reported in primary refractory HD. The progression-
free survival in 30 patients treated was 42% at 3.6 years with an overall survival of 60% at 
five years.
39
 
 
Summary : Based on the above and other studies, standard treatment for patients with 
refractory HD (i.e. less than a complete response after first line therapy), relapse within 12 
months of completing treatment or more than one relapse, is now HDC.  There may also be 
a survival benefit for patients who relapse more than one year after completing first line 
chemotherapy. The EORTC are currently carrying out a randomised trial of conventional 
salvage versus HDC in relapsed HD. 
 
2.5.2 HDC in First Remission Hodgkin’s Disease 
A number of independent prognostic factors have been identified for HD and a prognostic 
score constructed.
40
  A number of studies looking at the role of HDC in first complete 
remission or good partial remission are ongoing.  These include studies by the EBMT and 
by the Scottish and Newcastle Lymphoma Group. 
 24 
 
2.5.3 Timing of HDC in Relapsed Hodgkin’s Disease 
The optimum timing for HDC in relapsed HD remains undecided.  There has been a 
tendency to adopt a similar strategy to NHL, i.e. to demonstrate chemosensitivity and 
reduce tumour bulk with re-induction chemotherapy.  However, there is some evidence that 
in fit patients it may be better to proceed directly to a high dose procedure.  Bierman et al. 
reported the use of ABMT or PBPC in 84 patients with HD in first relapse.
41
  All patients 
were transplanted with the CVB regimen.  73 of the 84 patients received a brief course of 
chemotherapy before coming to HDC.  63% of patients achieved a complete response 
following the HDC and there was a 4% treatment related mortality. The progression-free 
survival at four years for this group was 43%. A sub-set of patients who came immediately 
to transplant without any low-dose salvage therapy had a failure-free survival at four years 
of 91%. 
 
A recently presented review of the EBMT database suggested that in patients with first 
relapse, those who had a relapse greater than one year still benefited from HDC when 
compared with standard salvage in historical controls.  Furthermore, there was no benefit to 
demonstrating chemosensitivity and the recommendation was that patients should proceed 
to HDC immediately.  Five year actuarial survival in the 139 patients was 49.4%, 
progression-free survival 44.7%.    
 
There appears to be an increasing body of evidence that in patients with relapsed HD, it is 
advantageous to proceed directly to HDC without re-induction chemotherapy to demonstrate 
chemosensitivity.  However, many patients with relapsed HD may not be fit for an immediate 
high dose procedure.  Because of disease-related problems in these patients re-induction 
chemotherapy is still indicated. 
 
2.6 Source of Progenitors in Non-Hodgkin’s Lymphoma; Autologous Versus 
Allogeneic (Donor) 
 
Although most patients with lymphoma have been transplanted with autologous bone 
marrow or peripheral blood stem cell, approximately 10% of transplants have been 
performed with allogeneic marrow.  The use of allogeneic marrow (alloBMT) eliminates the 
possibility of infusing malignant cells into the transplant recipient.  In addition, autologous 
bone marrow transplantation (ABMT) has potential for a graft versus lymphoma effect 
similar to the graft versus leukaemia effect seen in some types of leukaemia.  
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Disadvantages of ABMT include high transplant related morbidity and mortality due to graft 
versus host disease.  In addition, only one third of patients will have a suitably matched 
donor and patients may be considered too old for ABMT. 
 
Investigators at John Hopkins University, USA, reported outcomes in patients undergoing 
allogeneic transplantation for NHL and HD.
43
  The relapse rate was 46% for recipients of 
autologous bone marrow compared with 18% for patients who received allogeneic marrow.  
However, the higher relapse rate in patients who received autologous marrow was offset by 
higher transplant related mortality in patients who received allogeneic transplants.  The EFS 
in the two groups was not significantly different.   
 
A case controlled study of patients reported to the EBMT matched 101 ABMT patients with 
101 patients who underwent allogeneic transplantation. The progression-free survival was 
similar in both types of transplants (46% vs 49% respectively). The overall relapse and 
progression rate for the allogeneic BMT was 23% compared with 38% in the ABMT patients, 
but failed to statistical  significance.
42
 
 
2.7 Indications for High Dose Chemotherapy in Lymphoma  
 
The EBMT has drawn up draft accreditation guidelines for HDC Centres and it is likely that 
these will be accepted as minimum standards. Indications for HDC have also been drawn up 
by the EBMT and it is likely that these will be adopted as the current indications for HDC.  
An edited version of these guidelines for lymphoma is shown below. 
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Table 4 EBMT Draft Guidelines for High Dose Chemotherapy Indications in 
Lymphoma 
 EBMT DRAFT RECOMMENDATIONS 
 
Trent WGAP 
Clinical 
Interpretation 
Disease Status Allogeneic - 
Sibling 
Allogeneic - 
Unrelated 
Autologous Autologous 
Intermediate/High 
grade NHL 
Initial treatment  -  -  -  CT 
 First partial response  -  -  -  CT 
 First complete remission 
(consolidation) 
 R                  CT  R  CT 
 First relapse  R                        D  R  R 
Low grade NHL First complete remission  NR                    
 
 NR   CT  CT 
 First relapse  CT  NR  CT  CT 
 Second complete 
remission 
 CT  NR  CT  CT 
Lymphoblastic 
NHL 
First complete remission  CT   D  R Not Discussed 
 Established relapse  D  NR  NR Not Discussed 
Mantle Cell 
Lymphoma 
First complete response  R  -  R Not Discussed 
Hodgkin's Disease First relapse  R/CT   D  R  R 
 Refactory disease - no 
response 
 CT                        D  D  CT 
 Second or subsequent 
relapse 
 R/CT                    D  R  R 
 First complete remission 
(consolidation) 
 D                NR  CT  CT 
 First partial response  R/CT   R  R 
      
CT  Clinical trial The value of transplants in this group has not yet been clearly defined. Patients 
should be treated as part of a clinical trial. 
   
R Recommended The results of such procedures are well defined and compare favourably (often 
better) than standard treatment. 
   
D    Developmental There is little or no national experience of HDC in this setting. 
   
NR Not 
recommended 
There is some overlap with the developmental recommendation. It essentially 
covers diseases not usually treated with HDC and includes early stage disease for 
which the additional risk of HDC is not  justified 
Note: There are still questions remaining over the exact interpretation of EBMT guidelines in HD.
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3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 General 
 
From the review of the clinical evidence, it is apparent that HDC is indicated as a clinically 
effective and recommended therapy in four specific patient prognosis groups: 
 
 Non-Hodgkin’s Lymphoma - First relapse 
 Hodgkin's Disease - First relapse 
 Hodgkin's Disease - Second or subsequent relapse 
 Hodgkin's Disease - Primary refractory disease (i.e. incomplete response) 
 
HDC is also recommended in the EBMT draft guidelines for Lymphoblastic NHL and mantle 
cell lymphoma. As this represents a very small proportion of lymphoma, no separate cost 
benefit has been considered. 
 
Non-Hodgkin’s low grade and first complete response HD remain areas where clinical 
benefit has yet to be proven through randomised controlled trial evidence. 
 
The following considers the level of patient benefit that can be derived in each patient group 
from the trial evidence. 
 
3.2 Benefits of High Dose Chemotherapy in First Relapse Non-Hodgkin’s 
 Lymphoma  
The main evidence for benefit in this group comes from the Parma study.
11
 The study 
provides evidence of both overall survival and disease-free survival at the five year point. 
Unfortunately, the study does not provide any exact data points within the five year period, 
but does present a Kaplan-Meier curve of the survival data. Using the published data and 
graphs both benefits have been estimated in order to make a direct comparison between 
the standard chemotherapy arm and the HDC study arm. 
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Figure 5   Non-Hodgkin’s’s Lymphoma Parma Study - Overall Survival Curves 
High Grade 1st Relapse NHL - Survival Curve - 
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Using these curve estimates it is predicted that the marginal survival benefit of HDC over 
standard chemotherapy is approximately 13 months (49 months c.f. 36 months) after a 
period of 75 months, which translates into a 1.1 life year gained (LYG). The estimate is 
taken as the difference between the area under the curve up to the end of trial results, in 
this case 75 months. In the absence of trial data, the area under the curve is taken using 
straight line interpolations between data points taken at 15 month intervals from the original 
Kaplan-Meier curves.  
 
In a similar way the disease-free survival data can also be used to make comparisons. 
 
Figure 6  Non-Hodgkin’s’s Lymphoma Parma Study - Disease-free Survival 
Curves 
High Grade NHL First Relapse - Progression-free 
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Using these curve estimates it is predicted that the marginal disease-free survival benefit of 
HDC over standard chemotherapy is approximately 17 months (39 months c.f. 22 months). 
 
Calculating benefits in this way ignores any benefit which may follow on from the trial end-
point. Whilst these benefits carry a degree of uncertainty, as they remain unrecorded in trial, 
it is still appropriate to estimate their likely magnitude under a range of different assumption 
scenarios.  
 
The most pessimistic case would be that immediately after the 75 months trial period the 
HDC treatment arm moves immediately to the outcome curves of the conventional treatment 
group.  This is obviously highly unlikely as it would require an immediate increase in death 
rate. As the survival curves flatten out for both treatment arms the five year trial survival has 
been taken to indicate a long-term cure. Taking the overall survival curve it has been 
assumed that the benefits of treatment continue at the same level, representing no further 
lymphoma related mortality, for a range of period from five years to 30 years at which point 
the two treatment groups are assumed to merge together. 
 
Figure 7   Projected Survival Benefits of High Dose Chemotherapy 
High Grade 1st Relapse NHL - Survival Curve - PARMA STUDY 
(including 5 year projected benefits)
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The graph above shows the projected outcome curve for the five year projection scenario.  
 
Adopting these assumption scenarios beyond the 75 month point, a set of revised estimates 
of marginal survival benefit are arrived at, as presented in the table below. 
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Table 5  Parma Trial Survival Benefits 
Forward 
Projection of End 
of Trial Benefits 
Survival Benefit in Months LYG 
  5 year  27mths (85mths c.f. 58mths) 2.3 
10 year  40 mths (116mths c.f. 76mths) 3.3  
20 year  66 mths (182mths c.f. 116mths) 5.5  
30 year  82 mths (224mths c.f. 142mths) 6.8  
 
 
In a similar consideration of disease-free survival: 
 
Figure 8  Projected Disease-free Benefits of High Dose Chemotherapy 
High Grade 1st Relapse NHL - Survival Curve - Parma Study 
(including 5 year projected benefits)
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Adopting the same scenarios about the benefits beyond the 75 month point, revised 
estimates of marginal survival benefit are arrived at. 
 
 31 
Table 6  Parma Trial Event-free Survival Benefits 
Forward 
Projection of End 
of Trial Benefits 
Event-Free Benefit in Months LYG 
5 years  37 mths (67mths c.f. 30mths) 3.1  
10 years  55 mths (92mths c.f. 37mths) 4.6  
20 years  92 mths (144mths c.f. 52mths) 7.7  
30 years  116 mths (178mths c.f. 62mths) 9.7  
 
The table below summarises the estimated clinical benefits derived from the Parma study. 
 
Table 7  Clinical Benefits of Parma Study 
Benefit Based on Trial 
Period Only 
Including Short-term 
Benefit Estimates 
(5 years) 
Including Long-term 
Benefit Estimates 
(30 years) 
Overall Survival 13 mths 27 mths   82 mths 
Event-Free Survival 17 mths 37 mths 116 mths 
    
 
3.3 Benefits of High Dose Chemotherapy in Hodgkin’s Disease  
 
As stated, the studies and trials related to HD tend to consider groups of mixed patients 
combining treatment refactory with relapse patients. Two possible sources of clinical benefit 
are considered. 
 
BNLI-Linch RCT Trial 
 
The Linch trial
30
 is the only published RCT considering HDC in HD. The trial considers a 
mixed patient group consisting of 40 treatment failed patients, 26 short of full recruitment 
due to patient refusal in favour of HDC. The two arms compared HDC based on 
BEAM+ABMT against mini-BEAM (lower dosage of the same drug combination).  
 
The survival benefit is shown in the following graphs with and without a five year extended 
benefit approximation. 
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Figure 9  High Dose Chemotherapy Survival Benefit in Relapses/Treatment 
Failure Hodgkin’s Disease - Linch Randomised Controlled Trial 
Hodgkin's Disease high risk/relapse - Survival Curve - Linch RCT
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From these graphs using the same area under the curve approximation methodology as 
used in NHL, it is estimated that, using purely the trial data, the marginal survival benefit is 
10 months (66 months c.f. 56 months). 
 
Figure 10 High Dose Chemotherapy Survival Benefit in Relapses/Treatment 
Failure Hodgkin’s Disease - Linch Randomised Controlled Trial 
Hodgkin's Disease high risk/relapse - Survival Curve - Linch RCT 
 (inc projected 5 year benefits)
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A range of projected benefit scenarios considering outcome 5, 10, 20 and 30 years beyond 
the trial end-point have also been considered. The analysis includes a standard mortality for 
each projected year and again compares the area under the curve up to the point where the 
two treatment arms merge. The results of this analysis are shown in the following table. 
 
Table 8  BNLI-Linch Trial Survival Benefits 
Forward 
Projection of End 
of Trial Benefits 
Survival Benefit in Months LYG 
5 years  28 mths (92mths c.f. 64mths) 2.3  
10 years  45 mths (136mths c.f. 91mths) 3.8  
20 years  78 mths (220mths c.f. 142mths) 6.5  
30 years  105 mths (290mths c.f. 184mths) 8.8  
 
 
Chopra Study 
 
Although the Linch RCT is the only randomised trial, there are a number of retrospective 
studies and patient follow-up studies which have monitored and observed the benefits of 
HDC in this patient group. The largest of these is the Chopra study
31
 which followed up eight 
years’ data related to 155 poor risk HD patients, who had received BEAM treatment with 
ABMT. All these patients had partial response or relapse on conventional chemotherapy. 
 
The following compares these observational data to the findings of another study, Longo et 
al.,
29
 which reported the low probability of cure from standard chemotherapy treatment in a 
similar mix of treatment resistant and relapsed patients. This study noted a 17% survival 
rate at five years on standard therapy, matching other reported series. 
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Figure 11 Benefits of High Dose Chemotherapy in Hodgkin’s Disease - Chopra c.f. 
  Longo Study  
Hodgkin's Disease high risk/relapse - Survival Curve - Chopra 
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From these graphs using the same area under the curve approximation methodology and 
trial data only, the marginal survival benefit is 11 months (65 months c.f. 56 months). 
 
 
Figure 12 Benefits of High Dose Chemotherapy in Hodgkin’s Disease - Chopra c.f. 
  Longo Study 
Hodgkin's Disease high risk/relapse - Survival Curve - Chopra Study 
(inc projected 5 year benefits)
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By including an extra five years’ projected benefits at a constant rate before bringing the 
HDC group back to the standard treatment arm, this marginal survival benefit increases to 
30 months (86 months c.f. 56 months). 
 
Table 9  Chopra - Longo Study Comparison Survival Benefits 
Forward 
Projection of End 
of Trial Benefits 
Survival Benefit in Months LYG 
  5 years   30 mths (85mths c.f. 55mths) 2.5  
10 years   52 mths (118mths c.f. 66mths) 4.3  
20 years   95 mths (181mths c.f. 86mths) 7.9  
30 years 132 mths (234mths c.f. 102mths) 11.0  
 
The following table summarises the clinical benefits of HDC in Hodgkin’s Disease. 
 
Table 10 Clinical Benefits of High Dose Chemotherapy in Relapsed and Poor  
  Prognosis Hodgkin’s Disease 
Benefit Based on trial 
period only 
Including short-term 
benefit estimates 
(5 years) 
Including long-term 
benefit estimates 
(30 years) 
Overall Survival - Linch RCT 
(5 year study follow-up) 
10 months 28 months 105 months 
Overall Survival - Chopra 
Study c.f. Longo Study 
(6 year study follow-up) 
11 months 30 months 130 months 
 
It is interesting that both the Randomised Controlled Trial and the observational 
retrospective patient follow-up show similar survival benefits. For the purpose of the 
economic evaluation, the analysis is limited to the Linch randomised controlled trial evidence 
only. 
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3.4 Cost of High Dose Chemotherapy 
The relative costs of treatment for lymphoma have been sourced from Weston Park 
Hospital, Sheffield and are based on a combination of drug, staffing and bed costs (where 
appropriate). 
 
The significant areas of difference between standard chemotherapy and HDC regimens are 
the need for the harvesting procedure and the requirement for in-patient and day case 
facilities/care. 
 
The cost of providing stem cell harvesting and HDC is estimated at £15,600, based on 
general extra contractual charges for procedures. This cost is appropriate for the majority of 
HDC in both Non-Hodgkin's Lymphoma and Hodgkin's Disease cases as most patients have 
the same type of therapy. 
 
The cost of providing a standard chemotherapy regimen is estimated at between £1,200 - 
£1,500. The cost of standard salvage chemotherapy is calculated from the cost of the drugs 
for one particular regimen including a 50% chance of admission because of neutropenic 
fever. It does not include any in-patient costs which may be associated with the 
chemotherapy alone. Therefore, it can be considered to be an underestimate of the 
treatment cost. 
 
Another important point is that standard dose salvage therapy is successful in the minority of 
patients only. The majority of patients, around 70%, will relapse again needing further 
treatment, blood transfusions, radiotherapy, analgesia etc.  High dose patients who relapse 
tend to have very aggressive disease and do not survive for very long. Therefore, the cost of 
palliative care in the standard therapy patients is likely to be higher than calculated. 
 
In an attempt to quantify the level of relapse costs, the patient records of four patients who 
had standard chemotherapy for HD with a later event of relapse were reviewed. The patient 
records identified areas of resource use including: palliative chemotherapy, radiotherapy, 
hospital admissions, blood tests, scans, blood transfusions, antibiotics etc. Based on these 
records, it is calculated that the mean average cost of relapse treatment is around £9,500, 
although costs ranged from £4,000 to £15,000. Importantly, this cost estimate does not 
include any hospice costs or costs outside the secondary care sector. 
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Although it is important to recognise these very real extra support costs of relapse under 
standard therapy, the economic analysis has been based firmly on first line treatment costs 
only. On a one-to-one comparison, the marginal cost of a single course of HDC is estimated 
at £14,100-£14,400. There are no other differences in costs envisaged in the provision of 
HDC as the infrastructure to support treatment remains the same. 
 
3.5 Cost-Benefit of High Dose Chemotherapy in Non-Hodgkin’s’s Lymphoma 
 
In considering the cost benefits of adopting HDC in first relapse NHL, the overall survival 
benefit is compared with the implied marginal costs. The marginal survival benefit as implied 
by the trial data only is considered first. This is in effect assuming that, at the 75 month 
point, the HDC cohort reduces immediately to the survival level of the standard 
chemotherapy treatment group. This is obviously pessimistic, but represents the data that 
are known and reported in the literature.   
 
Table 11 Cost-effectiveness of High Dose Chemotherapy in Non-Hodgkin’s  
  Lymphoma: Trial Based Data 
Cost-effectiveness Based 
on Trial Data Only  
(75 Months) 
Standard 
Chemotherapy 
High Dose 
Therapy 
Marginal 
Survival 
Analysis 
Therapy Cost £1,500 £15,600 £14,100 
Survival (area under the 
curve estimate)  
36 months 49 months 13 months 
3.0 LYG 4.1 LYG 1.1 LYG 
Marginal Cost per LYG - - £12,818 
 
Based on this analysis it is predicted that HDC provides a marginal 1.1 LYG  per patient at 
an increase in treatment cost of £14,100. This translates into a cost per LYG of £12,818. 
 
Consideration can also be given to this analysis taking into account the predicted extended 
benefits based on the five year projection of ongoing treatment benfits. At the five year 
point, the HDC group is reverted to standard chemotherapy survival levels. Under this 
scenario the marginal survival benefit increases to 2.3 LYG. 
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Table 12 Cost-effectiveness of High Dose Chemotherapy in Non-Hodgkin’s 
   Lymphoma: Extended Benefits Assumed 
Benefit Standard 
Chemotherapy 
High Dose 
Therapy 
Marginal 
Analysis 
Therapy Cost £1,500 £15,600 £14,100 
Survival (area under the 
curve estimate)  
58 months 85 months 27 months 
4.8 LYG 2.5 LYG 2.3 LYG 
Marginal Cost per LYG - - £6,130 
 
The cost per LYG including 5 year projected benefits  = £6,130 
The cost per LYG including 10 year projected benefits  = £4,272  
The cost per LYG including 20 year projected benefits  = £2,563 
The cost per LYG including 30 year projected benefits  = £2,074 
 
These figures compare favourably with existing interventions and fall well below the 
commonly quoted £20,000 per LYG threshold.  
 
3.6 Sensitivity of Cost per Life Year Gained in Non-Hodgkin’s Lymphoma 
The following graph shows the sensitivity of cost per LYG when considered against the cost 
of HDC. For the purpose of the sensitivity analysis, the clinical benefits have been restricted 
to those suggested by the trial data only; projections of benefit beyond the end of trial point 
have not been included. 
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Figure 13 Sensitivity of Cost per Life Year Gained in Non-Hodgkin’s Lymphoma 
Non-Hodgkin's Lymphoma : Sensitivity of Cost-effectiveness 
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Assuming the clinical benefits are as represented in the Parma trial, the cost-effectiveness 
of HDC remains below £20,000 even when the cost of a HDC treatment is increased to 
£20,000. 
 
Consideration has also been given to a scenario where the clinical benefits are only half of 
those predicted in the study. In this case the cost per LYG rises to around £25,000. 
 
The graph can also be used to estimate the cost-effectiveness if the five year projected 
benefits beyond the trial data are included. In this case a 2.3 LYG is predicted which would 
place the sensitivity line below all three lines shown on the graph. At this level of benefit the 
cost-effectiveness remains under £10,000 at the range of HDC marginal costs explored 
(£10-20,000). 
 
3.7 Cost Benefit of High Dose Chemotherapy in Hodgkin’s Disease 
 
In considering the cost benefits of adopting HDC in relapsed and poor prognosis HD the 
overall survival benefits are compared with the implied marginal costs. The marginal survival 
benefit, as implied by the Linch trial data only, is considered first. This is, in effect, assuming 
that at the 54 month point the HDC cohort reduces immediately to the survival level of the 
standard chemotherapy treatment group. This is obviously pessimistic, but represents the 
data that are known and reported in the literature.   
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Table 13  Cost-effectiveness of High Dose Chemotherapy in Hodgkin’s Disease: 
  Trial Based Data 
Cost-effectiveness Based 
on Trial Data Only  
(75 months) 
Standard 
Chemotherapy 
High Dose 
Therapy 
Marginal 
Survival 
Analysis 
Therapy Cost £1,500 £15,600 £14,100 
Survival (area under the 
estimate)  
56 months 66 months 10 months 
4.7 LYG 5.5 LYG 0.8 LYG 
Marginal Cost per LYG - - £17,625 
 
 
Based on this analysis it is predicted that HDC provides a marginal 0.8 LYG per patient at 
an increase in treatment cost of £14,100. This translates into a cost per LYG of £17,625. 
 
Consideration can also be given to this analysis taking into account the predicted extended 
benefits based on the five year projection of ongoing treatment benefits. At the five year 
point the HDC group is reverted to standard chemotherapy survival levels. Under this 
scenario the marginal survival benefits increase to 1.6 LYG. 
 
Table 14 Cost-effectiveness of High Dose Chemotherapy in Hodgkin’s Disease: 
  Extended Benefits Assumed 
Benefit Standard 
Chemotherapy 
High Dose 
Therapy 
Marginal 
Analysis 
Therapy Cost £1,500 £15,600 £14,100 
Survival (area under the 
curve estimate)  
64 months 92 months 28 months 
 5.4 LYG 7.7 LYG 2.3 LYG 
Marginal Cost per LYG - - £6,130 
 
 
The cost per LYG including 5 year projected benefits  = £6,130 
The cost per LYG including 10 year projected benefits  = £3,710  
The cost per LYG including 20 year projected benefits  = £2,170 
The cost per LYG including 30 year projected benefits  = £1,602 
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These figures compare favourably with existing interventions and fall below the commonly 
quoted £20,000 per LYG threshold.  
 
3.8 Sensitivity of Cost per Life Year Gained in Hodgkin’s Disease 
The following graph shows the sensitivity of cost per LYG when considered against the 
marginal cost of HDC. For the purpose of the sensitivity analysis, the clinical benefits have 
been restricted to those suggested by the trial data only. Projections of benefit beyond the 
end of trial point have not been included. 
 
Figure 14 Sensitivity of Cost per Life Year Gained in Hodgkin’s Disease 
Hodgkin's Disease : Sensitivity of Cost-effectiveness
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Assuming the clinical benefits are as represented in the Linch trial, the cost-effectiveness of 
HDC remains below £20,000 until the costs of HDC treatment are increased to around  
£18,000. 
 
Consideration has also been given to a scenario where the clinical benefits are only half of 
those predicted in the study. In this case the cost per LYG rises to around £30,000 at the 
current HDC marginal cost. 
 
The graph can also be used to estimate the cost-effectiveness if the five year projected 
benefits beyond the trial data are included. In this case a 2.3 LYG is predicted which would  
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place the sensitivity line below all three lines shown on the graph. At this level of benefit the 
cost-effectiveness remains under £10,000 at the range of HDC marginal costs explored 
(£10-20,000). 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
The options for purchasers can be summarised as follows: 
 
Option 1  Do not support the use of High Dose Chemotherapy in the treatment 
of all lymphoma, even within the context of clinical trials. 
 
This is an extreme option and would really fly in the face of the strong clinical evidence of 
effectiveness in a number of the disease sub-groups of lymphoma. It would also deny the 
exploration of potential benefits in other sub-groups, indicated in phase II and 
observational/retrospective cohort studies. 
 
Option 2  Support the use of High Dose Chemotherapy within clinical trials only 
across all levels of lymphoma, both Non-Hodgkin's Lymphoma and Hodgkin's 
Disease. 
 
The case for the use of HDC with ABMT/PBSCT has certainly been strongly indicated in a 
number of lymphoma groups, establishing it as the therapy option of choice in patients with 
suitable functional status to tolerate HDC. However, there remain some areas where the 
benefits are very uncertain and remain speculative. An example of this would be low grade 
lymphoma and partial response high grade lymphoma. 
 
Option 3  Support the usage of HDC for lymphoma as suggested by the EBMT 
   guidelines. 
 
The EBMT guidelines have been brought together to reflect the current state of treatment 
for lymphoma, and other malignancies, across Europe. It is expected that these guidelines 
will shortly become a strong measure by which centres will be expected to conform. The 
guidance recommends the use of treatment in a number of clear randomised controlled 
trials proven disease groups, whilst retaining a clinical trial basis for those where evidence is 
less clear cut. 
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Option 4 Support the use of HDC for lymphoma as suggested in the clinical summary 
of the Guidance Note by the Trent Working Group on Acute Purchasing (i.e. 
include support for those areas felt to be proven ethically). 
 
In considering the EBMT guidelines together with their own clinical practice, the Trent 
Working Group on Acute Purchasing debated the relative merits of the guidelines. In the 
vast majority of cases the EBMT stance was confirmed with respect to clinical trial and 
recommended therapy. It was felt, however, that the case in high/intermediate grade 
lymphoma remained unproven other than in the clear evidence for use in relapsed patients. 
It was also felt that there were some specific disease types within low grade lymphoma 
which would never be subject to randomised trials.  
 
Summary 
It is the view of the clinical authors of this report that the most appropriate way forward is to 
support the use of HDC in those areas where trial evidence is clear cut and to continue 
support of clinical trials in those areas where benefits have been suggested from early trial 
data.  
 
Within the context of the Trent Working Group, the invited clinicians discussed as a group 
the suggested EBMT guidelines. On the whole they considered their interpretation of the 
evidence to match with the EBMT position. There was slightly weaker support for a full 
recommended use in complete remission of high/intermediate grade lymphoma. A 
breakdown of the clinical view at the Trent seminar is provided alongside the EBMT 
recommendations in the evidence tables in Section 2. 
 
Importantly, the Group felt that there were a number of specific prognosis and disease 
groups where the early trial data had been so convincing that the clinical views suggested  
no further supporting randomised controlled trial data would be produced for ethical 
reasons. In these cases, the clinicians suggested that support for treatment should be 
provided without such evidence. It would be particularly important in these groups to track 
outcomes for use in the retospective analysis of treatments. 
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5. DISCUSSION AND CONCLUSIONS 
 
The use of HDC in the treatment of HD and NHL is already an established salvage therapy 
in certain prognostic groups. This Guidance Note helps to show the relative strengths and 
weaknesses of the trial and study evidence available in the public domain. 
 
It is clear that there are some areas of lymphoma where the benefit of HDC still remains 
unproven.  However, the strength of observational study evidence in some areas strongly 
supports the use of HDC, relapsed HD being a prime example.  
 
The costs of HDC are partially offset by the reduced likelihood of follow-up chemotherapy 
following relapse, as patients often succumb to the disease relatively quickly. The pattern of 
second/third and even fourth line treatment is common in standard first line chemotherapy. 
Importantly, the economic arguments for HDC have been based on initial therapy costs only, 
excluding any longer-term benefits of HDC from reduced follow-up treatment. 
 
The cost-effectiveness arguments for HDC in those areas of proven clinical efficacy, namely 
relapsed NHL and relapsed/partial response HD, hold firm even when tested under 
sensitivity analysis involving both costs and benefits. The cost-effectiveness ratios are 
certainly comparable with similarly supported therapies. 
 
The recently published EBMT recommendations help to provide a framework with which to 
consider the role of HDC and are likely to become a set of European standards.   
 
Finally, there also exists an ongoing HTA report, which considered the evidence for HDC in 
a range of cancers, including both HD and NHL. At the time of writing this report the HTA 
report is in the process of publication. However, a summary of its draft conclusions has been 
made available to the authors. 
 
A summary of the draft HTA report findings is given below: 
 
Intermediate/high grade Non-Hodgkin's Lymphoma 
 The report concludes that, in the light of the current single Parma trial
11
 evidence and 
with the lack of further ongoing trials, the use of HDC as a salvage therapy will be 
expected to continue as a standard therapy. 
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 As a direct first line therapy there is some evidence of effectiveness for the use of HDC, 
but not sufficient to determine the role as first line therapy. 
 
 As a first line therapy consolidating a complete response to standard chemotherapy, 
there is some evidence of effectiveness with both survival and progression-free survival 
benefits indicated in a single trial. Ongoing trials are in progress looking at post 
remission treatment with HDC. 
 
Low grade Non-Hodgkin's Lymphoma  
 In low grade NHL there is no real trial evidence currently available to support its use. 
 
Hodgkin’s Disease 
 The use of HDC is now regarded as standard salvage treatment in relapsed and 
refractory HD on the bases of the BNLI-Linch trial and the retrospective patient studies. 
The HTA considers the single trial to be too small on which to base firm conclusions. 
The report points towards an ongoing trial of HDC in relapsed patients (see appendix). 
 
 The use of HDC in consolidating first remission is not currently supported by published 
trial evidence and should be considered only within clinical trial.   
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6. USE OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION: SUMMARY MATRIX 
PATIENT GROUP PATIENT CRITERIA 
(GUIDELINES NOT PROTOCOLS) 
ESTIMATED 
FUTURE 
ACTIVITY 
OPPORTUNITY 
FOR COST 
SAVING 
AUDIT POINTS EFFECTS THAT COULD BE 
EXPECTED IN RELATION 
TO STARTING POINT 
 
COST-EFFECTIVENESS 
High/Intermediate 
Non-Hodgkin’s 
Lymphoma 
 
 
 
 
 
 
Low Grade  
Non-Hodgkin’s 
Lymphoma 
Patients in first relapse, second and 
subsequent relapse 
 
 
 
 
 
 
 
No patient groups currently indicated 
for HDC 
20-40 patients 
p.a. for a 
'typical' health 
authority may be 
suitable for HDC 
treatment. 
 
 
 
20-30 patients 
p.a. for a typical 
health authority. 
It is likely that 
patients who fail 
after HDC will not 
be re-challenged. 
 
 
Recording of 
long-term 
survival rates. 
Trial data suggest that an 
average of 1.1 LYG per 
patient is achievable against 
coventional chemotherapy. 
Cost per LYG is suggested at 
£12,818 when using trial data 
only. Projecting benefits forward 
to 5 years reduces this value to 
£6,130 per LYG. 
Hodgkin’s Disease 
 
Patients in first, second and 
subsequent relapse 
 
 
10 p.a. for a 
'typical' health 
authority may be 
suitable for HDC 
treatment. 
 
It is likely that 
patients who fail 
after HDC will not 
be re-challenged.  
 
Recording of 
long-term 
survival rates. 
Trial data suggest that an 
average of 0.8 LYG per 
patient is achievable against 
coventional chemotherapy. 
 
Cost per LYG is suggested at 
£17,625 when using trial data 
only. Projecting benefits forward 
to 5 years reduces this value to 
£6,130 per LYG. 
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APPENDIX  ONGOING TRIALS OF HIGH DOSE CHEMOTHERAPY IN NON-  
  HODGKIN’S LYMPHOMA/HODGKIN’S DISEASE 
 
HDC in Non-Hodgkin’s Lymphoma 
   Treatment regimens  
Trial code Status Disease Eligibility A B Planned 
Accrual 
EORTC-20901* Open Adult intermediate-and 
high-grade Non-
Hodgkin’s Lymphoma 
ADR, TENI, CTX, PRED, VCR, 
BLEO  
HDT + ABMT/PBSC BCNU, 
ETOP, CYT, CTX  
Radiotherapy 
ADR, TENI, CTX, PRED, 
VCR, BLEO  
radiotherapy 
300 
Scottish 
Lymphoma Group 
NHL V(a) 
Open High grade malignant 
lymphoma (good 
index) 
CHOP or VAPEC B  
HDT + PBSC  
L-PAM 
 
CTX, ADR, VCR, PRED  
or  
ADR, CTX, VCR, BLM, 
ETOP, PRED 
51 
patients 
entered to 
date 
EORTC - 20963* 
BNLI Hovon 35 
Open Stages 11 or IV 
follicular Non-
Hodgkin’s Lymphoma 
Induction therapy  
HDT + APBSC  
CTX, TBI  
Interferon maintenance 
Induction therapy  
 
 
Interferon maintenance 
469 
LY02 
UKLG/ANZLG/EB
MT 
Open Poor risk 
intermediate/high 
grade Non-Hodgkin’s 
Lymphoma 
HDT + ABMT CTX, ADR, VCR, PRED 500 
EBMT-ECUP Closed 
(30/04/97) 
Adult relapsed 
Follicular Non-
Hodgkin’s Lymphoma 
CTX, ADR, VCR, PRED  
 
HDT + ABMT/PBSC  
 
CTX, TBI 
CTX, ADR, VCR, PRED 200 
UKLG-LY01 Closed 
(30/04/97) 
Adult Lymphoblastic 
Lymphoma 
VCR,ADR,CTX,ASP PRED,  
MTX, DNR, CYT,  
or  
CTX,ADR,VCR,PRED, ASP,  
MTX, Radiotherapy 
 
HDT + ABMT/PBSC 
CTX,TBI 
or 
BCNU,ETOP,CTX l-PAM 
 
 
VCR,ADR,CTX,ASP, PRED,  
MTX, DNR, CYT,  
 
or  
 
CTX,ADR,VCR,PRED,ASP, 
MTX, Radiotherapy  
 
Maintenance 
200 
NCI-D78-017-
142* 
closed 
(01/01/81) 
Non-Hodgkin’s 
Lymphoma 
HDT + ABMT/AIBMT ADR, 
CTX, TBI  
 
MTX, CYT, TG, MTX  
or  
DAC, VCR 
ADR, CTX  
 
 
MTX, CYT, TG, MTX  
or  
DAC, VCR. 
28 
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   Treatment regimens  
Trial code Status Disease Eligibility A B Planned 
Accrual 
DUT-KWF-CKVO-
8518* 
Closed 
(01/01/93) 
Intermediate - and 
high-grade Non-
Hodgkin’s Lymphoma 
CTX, ADR, VCR, PRED  
 
HDT + ABMT  
CTX, TBI 
CTX, ADR, VCR, PRED 240 
MSKCC-89084* 
NCI-V89-0192 
Closed 
(12/01/93) 
Advanced low-grade 
Non-Hodgkin’s 
Lymphoma 
PRED,MTX,ADR,CTX,ETOP 
 
NM, VCR, PCZ, PRED 
 
HDT + ABMT 
CTX,ETOP, TBI 
PRED,MTX,ADR,CTX,ETO
P 
 
NM, VCR, PCZ, PRED 
Radiotherapy 
106 
    maximum planned accrual 2,785 
Source : Draft HTA report : Bone Marrow  & Peripheral Blood Stem-cell Transplantation for Malignancy 
 
* PDZ trial reference code 
Shaded boxes indicate open UK based and EORTC trials. 
 
HDC in Hodgkin’s Disease 
Trial Code Disease Eligibility HDT CC Planned Accrual 
 
HD01 
(EBMT and German 
Hodgkin’s Disease 
Study Group) 
Relapsed disease, responding to 
chemotherapy 
HDT + ASCT ADR,BLEO,VBL,DAC 
 or other standard regimen 
146 
EBMT Lymphoma 
working party 
First complete or good partial 
remission in poor prognosis 
patients 
HDT + ASCT - - 
HD3 
Scottish and 
Newcastle Lymphoma 
Group 
First complete remission in “poor 
prognosis” Hodgkin’s Disease, 
HDT + ABMT L-
PAM, ETOP 
VCR, ETOP, PCZ, CHL, 
ADR,BLM, PRED 
150 
   Maximum Planned Accrual >296 
Source : Draft HTA report : Bone Marrow  & Peripheral Blood Stem-cell Transplantation for Malignancy 
 
Shaded boxes indicate UK based and EBMT trials. 
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Other papers published by the Trent Institute for Health Services Research are listed below:- 
Guidance Notes for Purchasers  
 
96/01 Working Group on Acute Purchasing: The use of DNase in    £6.00 
 Cystic Fibrosis (1996) by JN Payne, S Dixon, NJ Cooper and   
 CJ McCabe.  
       
96/02 Working Group on Acute Purchasing: Tertiary Cardiology (1996)    £6.00 
 by J Tomlinson, J Sutton and CJ McCabe.  
  
96/03 Working Group on Acute Purchasing: The use of Cochlear     £6.00 
 Implantation (1996) by Q Summerfield and J Tomlinson.  
  
96/04 Working Group on Acute Purchasing: Statin Therapy / HMG Co-A   
  Reductase Inhibitor Treatment in the Prevention of Coronary Heart 
Disease 
£6.00 
 (1996) by MD Pickin, JN Payne, IU Haq, CJ McCabe, SE Ward, PR Jackson  
 and WW Yeo.  
  
97/01 Working Group on Acute Purchasing: The Clinical and Cost-effectiveness   £10.00 
 of Computed Tomography in the Management of Transient Ischaemic   
 Attack and Stroke (1997) by A Ferguson and CJ McCabe.  
  
97/02 Working Group on Acute Purchasing: Prostacyclin in the Treatment of    £10.00 
 Primary Pulmonary Hypertension (1997) by TW Higenbottam, SE Ward,   
 A Brennan, CJ McCabe, RG Richards and MD Stevenson.  
  
97/03 Working Group on Acute Purchasing: The Use of Riluzole in the Treatment £10.00 
 of Amyotrophic Lateral Sclerosis (Motor Neurone Disease) (1997) by J Chilcott,  
 P Golightly, D Jefferson, CJ McCabe and S Walters. 
 
  
97/04 Working Group on Acute Purchasing: Recombinant Factor VIII Versus    £10.00 
 Plasma Derived Factor VIII in the Management of Haemophilia A: An   
 Examination of the Costs and Consequences (1997) by C Green and   
 RL Akehurst.  
  
97/05 Working Group on Acute Purchasing: The Use of Cisplatin and Paclitaxel £10.00 
 as a First Line Treatment in Ovarian Cancer (1997) by SM Beard, R Coleman,   
 J Radford and J Tidy.  
  
97/06 Working Group on Acute Purchasing: The Use of Alpha Interferon in the   
 Management of Chronic Myeloid Leukaemia (1997) by RG Richards and  
£10.00 
 CJ McCabe.  
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97/07 Working Group on Acute Purchasing: Spinal Cord Stimulation in the    £10.00 
 Management of Chronic Pain (1997) by J Tomlinson, CJ McCabe and B Collett.  
  
97/08 Working Group on Acute Purchasing: The Use of Growth Hormone in Adults   £5.00 
 (1997) by JN Payne and RG Richards.  
  
97/09 Working Group on Acute Purchasing: A Review of the Use of Donepezil in the   £10.00 
 Treatment of Alzheimer’s Disease (1997) by FA Pitt, J Chilcott, P Golightly,   
 J Sykes, M Whittingham.  
  
97/10 Working Group on Acute Purchasing: The Use of Bone Anchored Hearing Aids   £10.00 
 (1997) by NJ Cooper, J Tomlinson and J Sutton.  
  
98/01 Working Group on Acute Purchasing: A Review of the Use of Current Atypical  
 Antipsychotics in the Treatment of Schizophrenia (1998) by S Beard, J Brewin,  
 C Packham, P Rowlands, P Golightly. 
£10.00 
  
98/02 Working Group on Acute Purchasing: Internal Fixation of Tibial Shaft and   
 Distal Radius Fractures in Adults (1998) by N Calvert, P Triffit, S Johnstone,  
 RG Richards. 
£10.00 
  
98/03 Working Group on Acute Purchasing: Tacrolimus and Mycophenolate Mofetil as 
 Maintenance Immunosuppressants following Renal Transplantation (1998) by  
 J Chilcott, M Corchoran, K Rigg, R Burden. 
 
£10.00 
  
 
Discussion Papers 
 
  
No. 1. Patients with Minor Injuries: A Literature Review of Options for their    £7.00 
 Treatment Outside Major Accident and Emergency Departments   
 or Occupational Health Settings (1994) by S Read.       
  
96/01  Working Group on Acute Purchasing: The Role of Beta Interferon    £7.50 
 in the Treatment of Multiple Sclerosis (1996) by RG Richards,   
 CJ McCabe, NJ Cooper, SF Paisley, A Brennan and RL Akehurst.   
  
96/02 The Mid-level Practitioner: A Review of the Literature on Nurse Practitioner   £10.00 
 and Physician Assistant Programmes (1996) by P Watson, N Hendey,   
 R Dingwall, E Spencer and P Wilson.    
  
96/03 Evaluation of two Pharmaceutical Care Programmes for People with   £10.00 
 Mental Health Problems Living in the Community (1996) by A Aldridge,     
 R Dingwall and P Watson.          
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97/01 Working Group on Primary and Community Care Purchasing : Report of   £10.00 
  the Sub-Group on the Promotion of Quality in Primary Care - Effective  
 Purchasing of Primary and Community Health Care: Promotion of Quality in   
 the Provision of Primary Care (1997) by S Jennings and M Pringle.  
  
97/02 Working Group on Primary and Community Care Purchasing : Report of   £10.00 
  the Sub-Group on Information Needs for Health Needs Assessment and   
 Resource Allocation (1997) by T Baxter, A Howe, C Kenny, D Meechan,   
 M Pringle, P Redgrave, J Robinson and  A Sims.  
  
98/01 Working Group on Primary and Community Care Purchasing : Hospital at Home - 
Lessons from Trent (1998) by I Perez, A Wilson, A Sims and R Harper. 
£10.00 
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